UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Roles of Cholesteryl-α-Glucoside Transferase and Cholesteryl Glucosides in Maintenance of Helicobacter pylori Morphology, Cell Wall Integrity, and Resistance to Antibiotics

mBio, 2018-11, Vol.9 (6)

2018

Volltextzugriff (PDF)

Adjuvant treatment of high-risk renal cell carcinoma: the jury is still out

Annals of oncology, 2018-10, Vol.29 (10), p.2030-2032

2018

Volltextzugriff (PDF)

Participation in One Health Networks and Involvement in the COVID-19 Pandemic Response: A Global Study

Frontiers in public health, 2022-02, Vol.10, p.830893-830893

2022

Volltextzugriff (PDF)

Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy

Cancer management and research, 2022-01, Vol.14, p.3071-3081

2022

Volltextzugriff (PDF)

Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts)

Annals of oncology, 2018-10, Vol.29, p.viii312-viii312

2018

Volltextzugriff (PDF)

Cholesterol glucosylation–based survival strategy in Helicobacter pylori

Helicobacter (Cambridge, Mass.), 2021-04, Vol.26 (2), p.e12777-n/a

2021

Volltextzugriff (PDF)

Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial

Expert review of clinical pharmacology, 2021-02, Vol.14 (2), p.261-268

2021

Volltextzugriff (PDF)

“We have to join forces…” – Current status and future European policies as discussed at the One Health EJP conference “Collaborating to face future One Health challenges in Europe”

CABI One Health, 2024-02, Vol.3 (1)

2024

Volltextzugriff (PDF)

Genotoxic Effect of Salmonella Paratyphi A Infection on Human Primary Gallbladder Cells

mBio, 2020-09, Vol.11 (5)

2020

Volltextzugriff (PDF)

Communicating and disseminating One Health: successes of the One Health European Joint Programme

Journal of medical microbiology, 2024-07, Vol.73 (7)

2024

Volltextzugriff (PDF)

Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma

Bone marrow transplantation (Basingstoke), 2009-01, Vol.43 (1), p.37-42

2009

Volltextzugriff (PDF)

2370P Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)

Annals of oncology, 2023-10, Vol.34, p.S1206-S1206

2023

Volltextzugriff (PDF)

2368P Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial

Annals of oncology, 2023-10, Vol.34, p.S1205-S1205

2023

Volltextzugriff (PDF)

654MO A phase II prospective trial of frontline cabozantinib in metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2)

Annals of oncology, 2021-09, Vol.32, p.S680-S680

2021

Volltextzugriff (PDF)

1624P Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide +/- zoledronic acid: The BonEnza study

Annals of oncology, 2024-09, Vol.35, p.S980-S980

2024

Volltextzugriff (PDF)

1470P Transcriptomic signature and immune infiltrate in metastatic collecting duct renal cell carcinoma patients treated with first-line cabozantinib: Results of exploratory endpoints from BONSAI trial (Meeturo 2)

Annals of oncology, 2022-09, Vol.33, p.S1218-S1219

2022

Volltextzugriff (PDF)

1785P Changes in bone mineral density, trabecular bone score and body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide plus/minus zoledronic acid: The BonEnza study

Annals of oncology, 2023-10, Vol.34, p.S965-S965

2023

Volltextzugriff (PDF)

1647TiP Antiandrogen therapy and TMPRSS2 status: How prostate cancer patients are protected from COVID-19 pandemic

Annals of oncology, 2021-09, Vol.32, p.S1162-S1162

2021

Volltextzugriff (PDF)

736P Updated data on patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sorafenib (SOR) vs observation (obs) after radical metastasectomy in the RESORT trial

Annals of oncology, 2020-09, Vol.31, p.S574-S575

2020

Volltextzugriff (PDF)

Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma

ImmunoTargets and therapy, 2020-01, Vol.9, p.273-288

2020

Volltextzugriff (PDF)

882PPotent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

861P - Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders

Annals of oncology, 2019-10, Vol.30, p.v336-v337

2019

Volltextzugriff (PDF)

Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders

Annals of oncology, 2019-10, Vol.30, p.v336-v337

2019

Volltextzugriff (PDF)

861PTime to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Genotoxic Effect of italic toggle="yes">Salmonella /italic> Paratyphi A Infection on Human Primary Gallbladder Cells

mBio, 2020-10, Vol.11 (5)

2020

Volltextzugriff (PDF)

1 – 25 von 277

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(235)
Mit Volltextzugriff
(211)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(159)
Life Sciences & Biomedicine
(115)
Humans
(108)
Female
(68)
Male
(66)
Middle Aged
(56)
Adult
(54)
Biological And Medical Sciences
(48)
Medical Sciences
(37)
Aged
(34)
Technology
(32)
Physical Sciences
(24)
Adolescent
(20)
Urology & Nephrology
(18)
Engineering
(16)
Aged, 80 And Over
(14)
Drug Therapy, Combination
(14)
Fundamental And Applied Biological Sciences. Psychology
(14)
Animals
(13)
Child
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Roles of Cholesteryl-α-Glucoside Transferase and Cholesteryl Glucosides in Maintenance of Helicobacter pylori Morphology, Cell Wall Integrity, and Resistance to Antibiotics

Adjuvant treatment of high-risk renal cell carcinoma: the jury is still out

Participation in One Health Networks and Involvement in the COVID-19 Pandemic Response: A Global Study

Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy

Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts)

Cholesterol glucosylation–based survival strategy in Helicobacter pylori

Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial

“We have to join forces…” – Current status and future European policies as discussed at the One Health EJP conference “Collaborating to face future One Health challenges in Europe”

Genotoxic Effect of Salmonella Paratyphi A Infection on Human Primary Gallbladder Cells

Communicating and disseminating One Health: successes of the One Health European Joint Programme

Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma

2370P Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)

2368P Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial

654MO A phase II prospective trial of frontline cabozantinib in metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2)

1624P Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide +/- zoledronic acid: The BonEnza study

1470P Transcriptomic signature and immune infiltrate in metastatic collecting duct renal cell carcinoma patients treated with first-line cabozantinib: Results of exploratory endpoints from BONSAI trial (Meeturo 2)

1785P Changes in bone mineral density, trabecular bone score and body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide plus/minus zoledronic acid: The BonEnza study

1647TiP Antiandrogen therapy and TMPRSS2 status: How prostate cancer patients are protected from COVID-19 pandemic

736P Updated data on patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sorafenib (SOR) vs observation (obs) after radical metastasectomy in the RESORT trial

Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma

882PPotent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts)

861P - Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders

Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders

861PTime to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders

Genotoxic Effect of italic toggle="yes">Salmonella /italic> Paratyphi A Infection on Human Primary Gallbladder Cells

Suchergebnisse filtern